Effect of red blood cell lysing agent in leukemia/lymphoma immunophenotyping by flow cytometry
RBC lysing agent’s effect on flow cytometry
DOI:
https://doi.org/10.21276/ak4wt566Keywords:
Leukemia/Lymphoma Immunophenotyping, RBC Lysing Agent, Lyse-Stain Wash ProtocolAbstract
Background: Getting rid of the red blood cells (RBC) is an integral part of flow cytometry (FCM)-based leukemia/lymphoma immunophenotyping. It is routinely done using an RBC lysing agent. RBC lysing has numerous consequences for the physical and immunophenotypic characteristics of the cell. We aimed to analyse the effect of different RBC lysing agents (with or without paraformaldehyde) on the antibody staining pattern. Methods: Three different RBC lysis preparations were used, namely BD FACSLyse (FL) and BD PharmLyse (PL), and a laboratory-prepared (home-brewed, HB) ammonium chloride-based reagent. A lyse-stain-wash protocol was used to prepare the cells, which were stained using a single tube of five-color antibodies (CD20-BV605, CD8-BV510, CD3-FITC, CD4-CD19-PeCy7, and CD45-APCR700). The effects of different lysings on different cellular characteristics, including the median fluorescence intensity (MFI) of CD45 in lymphocytes, CD3 in T lymphocytes, CD19 in B lymphocytes, CD20 in B lymphocytes, CD4 in T helper cells, CD8 in cytotoxic T cells, and CD4 in monocytes, were noted. Results: The duration needed for the RBC lysis using PL and HB was longer than that with FL (15–20 minutes vs. 10 minutes). The morphology of leukocytes was better preserved with the FL as compared to the HB and PL. The MFI of most of the antigens was similar for the HB and PL, but it was significantly lower for the FL. Conclusion: We should be aware of the changes that these agents may bring to the physical or immunophenotypic properties so as to choose the appropriate agent.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2024 International Archives of BioMedical and Clinical Research

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors are required to sign and submit the completed “Copyright transfer Form” upon acceptance of publication of the paper. This is determined by a publishing agreement between the author and International Archives of Biomedical and Clinical Research. These rights might include the right to publish, communicate and distribute online. Author(s) retain the copyright of their work. International Archives of Biomedical and Clinical Research supports the need for authors to share, disseminate and maximize the impact of their research.







